Marc Beer – article recap

LumeNXT announces Marc Beer as the new chairman of the board

 

LumeNXT, Inc. has announced the recruitment of Mr. Marc Beer as the new chairman of its board. Marc is a seasoned professional with more than 25 years’ experience in biotechnology, pharmaceuticals, and leadership. Marc is set to utilize his expertise to help the company achieve its goals in a timely manner.

 

LumeNXT is a privately held corporation that focuses on the development of surgical illumination products that are used in minimally invasive surgeries. LumeNXT has been at the forefront of the development of intracavity light emitting diode illumination. The advanced illumination platforms are mainly utilized by doctors to achieve more precision and efficiency in their work.

 

Compared to traditional techniques, targeted illumination enhances visualization, flexibility, and precision of the surgeon. This increases the chances of carrying out a successful procedure and ensures that it is carried out in a cost friendly and safe manner.

 

Speaking after his appointment, Marc Beer said that he was proud to be working with the dedicated and highly accomplished surgeons and engineers in LumeNXT. He praised the doctors and engineers for the various advancements that they had made to improve the LumeNXT platform. He also thanked the company and all staff for their dedication to ensuring that surgeries are conducted using minimally invasive procedures.

 

Paul Rhyne who is the co-founder of LumeNXT congratulated and praised Marc after the appointment. He also said that he had confidence in Marc and his ability to help the company meet its goals. Paul Rhyne said that Marc had already demonstrated an ability to lead by being highly successful in the various organizations that he has worked with. He also pointed out that Marc has repeatedly shown his ability to help startup companies turn a profit.

 

Marc Beer is also experienced in working with startup companies and helping them to go through the various growth phases that a company goes through smoothly. In the interview, Paul said that marc’s vast experience would help the company in the global commercial rollout and the company’s path to profitability.

 

About Marc Beer

 

Prior to joining LumeNXT, Marc had worked in several other organizations in and around the fields of biotechnology and pharmaceuticals. Marc Beer is the founding chairperson who also served as the CEO of Renovia, Inc. The company was formed to discover and deliver digital therapeutic and diagnostic kits for women suffering from pelvic floor disorders. Learn more: https://renoviainc.com/

 

Marc Beer holds a B.S from Miami University and began his early career by holding various positions in Genzyme. Genzyme is a specialty care company that works in the development of treatments for diseases that are difficult to diagnose or treat.

Mark Beer Renovia Inc. CEO

Mack Beer is a very experienced man in commercialisation and development of pharmaceuticals, devices, biotechnology, and diagnostics. He had over 25 years in the field and founded Renovia company together with Ramon Iglesias, Yolanda Lorie and MD in 2016. The company deals with lending capital funds to health care ventures.

 

In 2000 Mack Beer became the CEO of NASDAQ; VIAC which is a biotechnology company and specialises in preservation, collection and development of blood stem cells for the umbilical cord. Under his leadership, he grew the company from the start to rapidly growing and robust organisation it is today. The company has over 300 employees; it was later acquired by PerkinElmer in 2007.

 

Before becoming CEO to big organisations, Mack held different positions in his career. While CEO at ViaCell he was also serving in the board of directors at Erytec pharmaceuticals which is a public company.

 

In Genzyme, he was the vice president of global marketing. Here, he was in charge of the commercial launch of many products addressing many rare diseases around the globe. He also served in a marketing and sales position at Abbott Laboratories; Marc was also a member of Mass Life Science at commonwealth.

 

Renovia Inc. will be making new products dealing with pelvic floor disorder; the company just closed a $32 million Series B deal on Tuesday and addition of venture debt worth $10 million. The company is developing several therapeutical and diagnostic products to aid in the better treatment of pelvic floor disorders such as urinary incontinence which is common among women. Renovia had their first product in this line approved by the FDA in April.

 

Urinary incontinence is a rare type of pelvic floor disease that affects mostly women. Currently, over $250 million women around the world suffer from this disorder. Therefore, there is need for more awareness of this disorder and also better medication and better diagnostics.

 

Longwood fund, which is an investment firm that primarily focuses on health-care had invested earlier in Renovia; recently the company has joined series B round which is led by Perspective Advisers a New York-based company and Missouri-Ascension Ventures. This funding will be used for development and testing of their four new diagnostic and therapeutic products, which includes the generation of a new Leva device.

 

Mack Beer expressed his appreciation for the new support in the venture to better the diagnoses and treatment of pelvic floor disorders and hence save the lives of many women around the world. According to Marc, the combination of the two innovation and technology will help to develop a digital health programme that will provide customers with valuable data and information about new and available treatment options; this will help to drive understanding of this disorders and hence lower the healthcare cost in the long run. Learn more: https://www.bizjournals.com/boston/potmsearch/detail/submission/6457372/Marc_Beer

 

“Marc Beer Pioneering the Biotech Industry “

Marc Beer is the Chief Executive Officer of Renovia Inc. It is a pharmaceutical firm based in Boston. The firm is trying to develop a treatment for pelvic floor disorder. The disease like urinary infections affects a large percentage of women worldwide. Marc Beer founded Renovia Inc. and some of his associates. Marc Beer invested $32 million for use in coming up with new drugs for the treatment. Renovia Inc. is developing equipment and diagnosis that can be used to treat pelvic floor disorder. The firm came up with the first health care product, Leva to be used to diagnose the disease. The product got approved by the FDA a few months after it was released. Marc believes that with the correct diagnosis they can help millions of women.

Several therapeutic firms are coming together to help Renovia Inc. in developing a cure. One of these firms is the Longwood Fund that had initially invested in Renovia. Longwood Fund is an investment firm that only deals with medical institutions. Missouri-based Ascension Ventures and the New York Perspective Advisors lead the series B financing firms. The firms are funding the research on four new drugs for the treatment of pelvic floor disorder and would even like to make an upgrade of the Leva drug. Marc is delighted to be getting support from other therapeutic firms that are concerned with women’s health. The other firms are sharing the same vision as Renovia. Renova’s vision is to cure as many women as they can.

 

Marc believes that through combining ideas and technological equipment coming up with a cure will not be as difficult as it was initially. Marc is creating a platform that gives individuals a better understanding of pelvic floor disorder; its treatment options and affordable prices for patients that would like to get treatment. Marc Beer is not only the founder and CEO of Renovia Inc. but has also founded several other firms. In 2000 he founded ViaCell, a firm that collects, preserves and studies the umbilical cord stem blood cells. He led the coming to success by ensuring that there were continuous growth and profit margins.

 

Through Marc Beer’s management, the company has grown tremendously creating employment opportunities. ViaCell became publicized in 2005, and currently, PerkinElmer manages the firm. Marc is among the board of directors of various firms. He helps in making agreements on important decisions and even creates growth strategies for firms. He has worked with Genzyme and is currently working with Global Marketing as the Vice President. His principal role is to announce the launch of new products for the cure of significant diseases. Marc is also among the committee members for pharmaceutical firms that discuss significant health-related problems. Learn more: https://www.crunchbase.com/person/marc-beer